Mitochondria are the cell's powerhouses, and their dysfunction drives aging and age-related diseases. This makes them attractive targets for longevity interventions, but finding safe compounds that can therapeutically stress mitochondria without harming cells is challenging. This study addressed that gap by screening for compounds that activate the mitochondrial unfolded protein response (UPRmt)—a protective stress-response pathway that cells activate when mitochondrial function is threatened. The authors hypothesized that controlled activation of this pathway might extend lifespan, similar to how caloric restriction and some known geroprotectors work.
The researchers used a two-step screening approach in C. elegans (a standard model organism for aging research). They identified terbinafine and miglustat as compounds that robustly activate the UPRmt pathway by inducing expression of ATFS-1 (a key stress-response transcription factor) and other mitochondrial stress genes. Notably, both compounds also engaged the insulin/IGF-1 signaling (IIS) pathway and activated DAF-16 (a FOXO transcription factor), suggesting a coordinated stress response. The results showed lifespan extension and improved healthspan markers in worms. To test translational potential, they confirmed that both compounds induced similar mitochondrial stress responses in human HEK293T cells, suggesting the mechanism is conserved across species.
The findings are scientifically interesting because they identify a novel mechanism linking controlled mitochondrial stress to longevity: unlike canonical IIS activation (which can sometimes accelerate aging), these compounds appear to harness protective stress pathways. The discovery of existing, approved drugs (terbinafine for fungal infections, miglustat for Gaucher disease) that engage these pathways opens a drug-repurposing avenue that could bypass many developmental costs.
However, critical limitations constrain the current evidence. This is a first report with zero independent replications to date—a major concern in aging research, where false positives are common. The worm experiments are solid, but lifespan extension in C. elegans does not reliably predict human longevity benefits (only ~10% of compounds extended in worms also work in longer-lived organisms). The human cell work is preliminary (in vitro only; no functional aging markers measured). Dose-response relationships, toxicity at longevity-relevant concentrations, and off-target effects remain uncharacterized. The mechanisms are incompletely understood: why do these antifungal/metabolic drugs specifically activate mitochondrial stress? Possible off-target effects and whether the observed IIS activation is adaptive or problematic are unclear.
This work exemplifies the promise of drug repurposing in longevity research: identifying unexpected therapeutic properties of approved compounds. However, the path from C. elegans lifespan extension to human healthspan improvement is notoriously long, and single-lab discoveries require independent replication before strong claims are justified. The next steps would be validation in longer-lived organisms (mice), toxicology studies at proposed doses, mechanistic work to confirm on-target vs. off-target effects, and ultimately human clinical trials.
For longevity researchers, this represents a valuable screening result that warrants follow-up but should not yet be viewed as validated evidence for human benefit.
0 Comments
Log in to join the discussion.